

International Cancer Research Partnership (ICRP) Annual Report FINAL

- **Charity name:** International Cancer Research Partnership
- **Charity registration number:** 1204566
- **Report covering the period:** 1 April 2024 – 31 March 2025

Objectives and Activities

Summary of the purposes of the charity as set out in its governing document ¹
To promote and protect the good health of people affected by cancer and the public by promoting collaboration between cancer research funders across the world and by co-ordinating research into the causes, prevention, treatment and cure of all forms of cancer, to maximise the value and benefits of cancer research.
Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts ²
<ol style="list-style-type: none">1. Provision of a public database of global cancer research projects - classified by research and cancer type - that are funded by the partner organisations, to enable cancer researchers and funders to identify opportunities for collaboration, avoid duplication, and highlight gap areas where further investment is required to enhance research for the benefit of cancer patients and the public.2. Enhancing communication between cancer research funders to promote collaboration, share knowledge and maximise resources by avoiding duplicative activities. This is achieved through monthly online meetings for partners, an annual meeting, and provision of resources through the partner website and forum.3. Publish regular reports on global cancer research activity, to highlight opportunities to enhance research, for the benefit of partners, patients, policymakers and the wider public.
Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit ³
The trustees have complied with their duty to have due regard to the commission's public benefit guidance

Achievements and Performance

Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole ⁴

¹ SORP reference Para 1.17

² SORP reference Para 1.17 and 1.19

³ SORP reference Para 1.18

⁴ SORP reference Para 1.20

1. **Enhancing the database of cancer research**

In 2024-25, 54,438 new projects were uploaded to the database (an increase from 7701 in 2023-24) and updates processed for 306 projects. Essential maintenance was conducted for the website and database, and further enhancements were also made to the database search on the website to improve the user experience.

2. **Co-funding between partners**

To address identified gaps in cancer research, many of ICRP's members co-funded projects with other funders. Examples included CRUK & NCI (US); AECC (Spain) & WCR (Scotland); AECC (Spain), CRUK, AIRC (Italy); MRA (US) & RTFCCR (Switzerland).

3. **Publications, evaluations and analysis**

- a. **Metastatic Breast Cancer:** an ICRP sub-group continued working with the Metastatic Breast Cancer Alliance (MBCA), to analyse investment in metastatic breast cancer (MBC) research from 2014-2020. The report had already identified that previously (2000-2013), 7% of the \$15 billion in breast cancer research dollars globally was for MBC. In 2014-2020, 13% of all breast cancer research dollars was devoted to MBC and investment in treatment resistance had increased (see [summary](#)). Patient advocates identified five new priority areas to examine (research into: Survivorship, Pregnancy, Microenvironment, Brain & leptomeningeal disease, Treatment - rare sub-types) with the aim of producing a report for the MBCA partners' meeting in Spring 2026.
- b. **ICRP reports:** essential preparatory work was done to underpin future analyses on childhood cancer, survivorship and global landscape analyses.
- c. **Gender & PI:** an international sub-group of partner representatives in support of the [Lancet Commission on Women, power and cancer](#) analysed the gender of principal investigators in ICRP projects, in preparation for a publication later in 2025/early 2026.

4. **Membership and communications**

Newsletters were published via the website and distributed by email to potential new partners. Funding opportunities from partner organisations were highlighted on the [ICRP website](#) and by Twitter/X to attract global applicants. Discussions were ongoing with the European Commission on including funded projects that had been coded to research and cancer type as part of the Lancet Commission roadmap for cancer research in Europe in 2022 in the ICRP database. New potential partners were identified during the course of the year.

5. **Patient engagement**

Patient advocates led the identification of priority questions in the Metastatic Breast Cancer Analysis, and presented a panel at the May 2024 partner meeting.

6. **Annual and virtual meetings**

A hybrid in-person/remote partner meeting was held in Toronto in May 2024, on the theme "Doing More Together". Over 130 participants attended from 12 countries. Open sessions held on May 14th and 15th focused on Global Oncology - Challenging the Status Quo through Collaboration, Cancer Clinical Trials, AI in Cancer Research, Innovative cancer research funding models, Research Impact, Patient Engagement and Identifying and Funding Game-Changing Research. The

[meeting report](#) was published in June 2024 and a list of priority areas was produced to follow up during the year. Five virtual partner meetings were held with presentations from partners on topics of interest or collaborative funding opportunities.

7. **Organisation, finance & operations**

The process of migrating financial functions to a UK bank continued and the Charities Aid Foundation Bank (CAF Bank) was identified as the preferred option [Post AGM Note: Completed in August 2025]

Financial Review

Review of the charity's financial position at the end of the period	Para 1.21	See Fiscal Statement (Appendix)
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	6 month operational reserve for winding up operations
Amount of reserves held	Para 1.22	£80K (\$100K USD)
Reasons for holding zero reserves	Para 1.22	n/a
Details of fund materially in deficit	Para 1.24	n/a
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	n/a

Additional information (optional)

The charity's principal sources of funds (including any fundraising) SORP Para 1.47	Membership dues
--	-----------------

Structure, Governance and Management

Description of charity's trusts:		
Type of governing document	Para 1.25	Association Model Constitution
How is the charity constituted?	Para 1.25	Charitable Incorporated Organisation
Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees	Para 1.25	Skills audit

Reference and Administrative details



Charity name	International Cancer Research Partnership
Other name the charity uses	n/a
Registered charity number	1204566
Charity's principal address	International House, 10 Churchill Way, Cardiff, CF10 2HE, UK

Names of the charity trustees who manage the charity

Trustee Name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
Iain Frame		Resigned Sep 2024	
Kimberly Badovinac			
Katherine McKenzie			
Lynn Turner			
Richard Stephens			
Sarah McDonald			

Declarations


The trustees declare that they have approved the trustees' report above.
Signed on behalf of the charity's trustees

Signature(s)		
Full name(s)	Lynn Turner	Sarah McDonald
Position (e.g. Trustee, Secretary, Chair etc.)	Trustee	Trustee
Date	23/01/26	23/01/2026

International Cancer Research Partners (ICRP)

FINANCIAL REPORT for the period of April 1, 2024 - March 31, 2025



Chair, Finance Committee Kimberly Badovinac	Sponsor ICRP	As at March 31, 2025
Host Institution Canadian Partnership against Cancer		
SOURCES OF FUNDS	USD	USD(\$)
Balance of funds as of April 1, 2024	\$ 202,459.90	
Membership Fees for FY23/24 received in FY24/25 (Note 2)	8,000.00	
Membership Fees for FY24/25	25,000.00	
Total funds available for April 1, 2024 - March 31, 2025	A	\$ 235,459.90
EXPENDITURES INCURRED		
1) Salary and Benefits		
a) Consulting Fee	\$ 45,098.53	
	Subtotal	\$ 45,098.53
2) Operations		
a) ICRP webex & other subscriptions etc.	\$ 2,364.21	
b) Travel & Meeting expenses	12,745.10	
	Subtotal	\$ 15,109.31
Total expenditures incurred April 1, 2024 - March 31, 2025	B	\$ 60,207.84
UNSPENT BALANCE	A-B	\$ 175,252.06
TOTAL BALANCE USD		\$ 175,252.06
Unrealized foreign exchange losses (Note 1)		\$ (88,219.89)
Total Adjusted Balance USD		\$ 87,032.17
SIGNATURE		
<p>Note 1: As at March 31, 2025, the USD equivalent of the \$125,118.13 CAD balance in CPAC's account is \$87,032.17 USD using an exchange rate of 0.6956. This difference is due to the effect of accumulated currency fluctuation since August 1, 2013, the unrealized foreign exchange losses are \$88,219.89 USD.</p> <p>Note 2: FY23/24 membership fee of USD 8,000 from Japan Agency for Medical Research and Development was received on April 4, 2024 and was reflected in FY24/25 statement.</p>		
<p>I hereby certify that the funds received and the expenditures incurred were transacted wholly on behalf of the grantee, and that the supporting documents are available for monitoring purposes.</p> 		
<p>Jessie Yin, CPA ,CGA Controller, Finance & Administration Canadian Partnership against Cancer May 9, 2025 Date</p>		